Lymphoblastic Leukemia, Acute, Childhood Clinical Trial
Official title:
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
This is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL).
This study will utilize Marqibo® as a replacement for standard vincristine in combination with chemotherapy for children with relapsed ALL. The hypothesis is that the incorporation of Marqibo® with combination chemotherapy will be safe and feasible. In the context of this pilot study, overall outcomes and efficacy will be a secondary objective. It is hypothesized that data from this combination may show improved efficacy including, complete remission (CR), minimal residual disease (MRD) negativity, and progression free survival (PFS) rates and safety (i.e., neurotoxicity) in comparison to outcomes in historical regimens, including the UK ALL R3 with standard vincristine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05043571 -
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
|
Phase 1 | |
| Recruiting |
NCT05495035 -
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
|
Phase 1 | |
| Completed |
NCT01411267 -
AC220 for Children With Relapsed/Refractory ALL or AML
|
Phase 1 | |
| Completed |
NCT00991133 -
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
| Active, not recruiting |
NCT05440409 -
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
|
||
| Completed |
NCT01861002 -
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
|
Phase 1 | |
| Terminated |
NCT01100658 -
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
|
N/A | |
| Completed |
NCT01896752 -
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL
|
N/A | |
| Completed |
NCT01321346 -
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT01614197 -
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05429905 -
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03022747 -
Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
|
Phase 2 | |
| Active, not recruiting |
NCT03817320 -
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT05611086 -
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia
|
Phase 4 | |
| Terminated |
NCT01186328 -
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
| Completed |
NCT02906371 -
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
|
Phase 1 | |
| Recruiting |
NCT05038696 -
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
|
Phase 1 |